CORRECTION

Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States

Sarah S. Mougalian · Jonathan K. Kish · Jingchuan Zhang ·
Djibril Liassou · Bruce A. Feinberg

Published online: May 16, 2021
© Springer Healthcare Ltd., part of Springer Nature 2021

Correction to:
Adv Ther (2021) 38:2213–2225
<https://doi.org/10.1007/s12325-020-01613-6>

In the original article, there was an error in the reported CBR level in the Disease Response section on page 6. The correct value should read “The CBR was 56.7% (95% CI 52.3–61.0%)”.

The original article can be found online at <https://doi.org/10.1007/s12325-020-01613-6>.

S. S. Mougalian (✉)
Yale Medical School, Yale Cancer Center,
New Haven, CT, USA
e-mail: sarah.mougalian@yale.edu

J. K. Kish · D. Liassou · B. A. Feinberg
Cardinal Health Specialty Solutions, Dublin, OH,
USA

J. Zhang
Eisai Inc., Woodcliff Lake, NJ, USA